InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
Vancouver, British Columbia–(Newsfile Corp. – April 18, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of Dr. David G. Morgan, a renowned leader in neurodegenerative disease to its Scientific Advisory Board ("SAB") reinforcing the Company's commitment to advancing it's INM-901 program in the treatment of Alzheimer's disease.
不列顛哥倫比亞省溫哥華——（Newsfile Corp.，2024年4月18日）——稀有大麻素和專有大麻素類似物研究、開發、製造和商業化的領導者InMed Pharmicals Inc.（納斯達克股票代碼：INM）（“InMed” 或 “公司”）今天宣佈將神經退行性疾病領域的知名領導者戴維·摩根博士加入其科學顧問委員會（“SAB”））強化了該公司對推進其治療阿爾茨海默氏病的 INM-901 計劃的承諾。
Eric Hsu, InMed's SVP of Preclinical Drug Development, commented, "We are privileged to welcome someone of Dr. Morgan's stature to our SAB, which underscores the recent progress we've achieved in the INM-901 program. Dr. Morgan's significant contributions and pioneering breakthroughs have made him a leading authority in Alzheimer's research. His guidance and expertise will be invaluable as we advance to the next stages of development of our INM-901 program in the treatment of Alzheimer's."
InMed 臨床前藥物開發高級副總裁 Eric Hsu 評論說：“我們很榮幸歡迎像摩根博士這樣有地位的人加入我們的 SAB，這凸顯了我們最近在 INM-901 項目中取得的進展。摩根博士的重大貢獻和開創性的突破使他成爲阿爾茨海默氏症研究的主要權威。隨着我們進入阿爾茨海默氏症治療的 INM-901 項目開發的下一階段，他的指導和專業知識將是無價的。”
Biography
傳記
Dr. David Morgan is Director of the Alzheimer's Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. Dr. Morgan's research interests are Alzheimer's disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat the Alzheimer-related pathologies. Previously, he was CEO of the Byrd Alzheimer's Institute at the University of South Florida. While there, Dr. Morgan oversaw development of the Community-Based Memory Screening programs and the country's first mobile clinical trial unit for Alzheimer's disease.
戴維·摩根博士是阿爾茨海默氏症聯盟董事兼密西根州立大學轉化神經科學基金會教授。摩根博士的研究興趣是阿爾茨海默病、衰老和大腦功能。他因在免疫療法和基因療法治療阿爾茨海默氏症相關疾病方面的工作而獲得國際認可。此前，他曾擔任南佛羅里達大學伯德阿爾茨海默氏症研究所的首席執行官。在那裏，摩根博士監督了社區記憶篩查計劃的開發以及該國第一個針對阿爾茨海默氏病的移動臨床試驗單位。
Dr. Morgan received his undergraduate and graduate degrees from Northwestern University and spent 10 years at the University of Southern California before joining the University of South Florida in 1992. He has participated in over 90 grant-years of NIH funded research and published over 200 research articles. Dr. Morgan regularly sits on grant review panels for NIH and other agencies. In addition to his research activities, he has consulted with both major pharmaceutical and small biotechnology companies and also advised capital investment organizations regarding the most promising therapeutic approaches to curing Alzheimer's disease. He has also advocated nationally for additional Alzheimer's research funding through his role at Researchers Against Alzheimer's and with the Alzheimer's Association.
摩根博士擁有西北大學的本科和研究生學位，在南加州大學工作了10年，然後於1992年加入南佛羅里達大學。他參與了超過90年的美國國立衛生研究院資助的研究，並發表了200多篇研究文章。摩根博士經常擔任美國國立衛生研究院和其他機構的撥款審查小組成員。除了研究活動外，他還諮詢了大型製藥和小型生物技術公司，還就治療阿爾茨海默氏病的最有前途的治療方法向資本投資組織提供了建議。他還通過在抗阿爾茨海默氏症研究人員和阿爾茨海默氏症協會任職，在全國範圍內倡導增加阿爾茨海默氏症研究資金。
David Morgan's Publications:
大衛摩根的出版物：
Learn more about InMed's INM-901 program:
了解有關 InMed INM-901 計劃的更多信息：
About InMed:
關於 inMed：
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. We are a clinical-stage company developing a pipeline of proprietary cannabinoid-analog therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
InMed Pharmicals是稀有大麻素和專有大麻素類似物的製造、開發和商業化的全球領導者。我們是一家處於臨床階段的公司，正在開發專有的大麻素類似物療法產品線，致力於爲可能受益於大麻素類藥物的患者提供新的治療替代方案。欲了解更多信息，請訪問 www.inmedpharma.com。
Investor Contact:
Colin Clancy
Vice President, Investor Relations and Corporate Communications
T: +1 604 416 0999
E: [email protected]
投資者聯繫人：
科林·克蘭西
投資者關係和企業傳播副總裁
電話：+1 604 416 0999
E: [電子郵件保護]
Cautionary Note Regarding Forward-Looking Information:
關於前瞻性信息的警示說明：
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-091, INM-091's ability to treat Alzheimer's and the further development of InMed's INM-901 program.
本新聞稿包含適用證券法所指的 “前瞻性信息” 和 “前瞻性陳述”（統稱爲 “前瞻性信息”）。前瞻性陳述通常以 “期望”、“預期”、“相信”、“打算”、“潛力”、“可能”、“將” 等詞語和類似表述來識別，但並非總是如此。此類陳述基於管理層當前的預期，本質上涉及許多已知和未知的風險、不確定性和假設，其中許多是我們無法控制的。前瞻性信息基於管理層當前的預期和信念，存在許多風險和不確定性，這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。在不限制上述內容的前提下，本新聞稿中的前瞻性信息包括但不限於以下方面的陳述：INM-091 的功效、INM-091 治療阿爾茨海默氏症的能力以及InMed INM-901 計劃的進一步發展。
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
此外，還有一些已知和未知的風險因素可能導致InMed的實際業績、業績或成就與本文包含的前瞻性信息所表達或暗示的任何未來業績、業績或成就存在重大差異。InMed的10-K表年度報告以及向美國證券交易委員會提交的其他文件中披露了對InMed獨立業務面臨的風險和不確定性的完整討論 www.sec.gov。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
此處的所有前瞻性信息均受本警示聲明的全面限制，除非法律要求，否則InMed不承擔任何修改或更新任何此類前瞻性信息或公開宣佈爲反映未來業績、事件或發展而對本文包含的任何前瞻性信息進行任何修訂的結果的義務。
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/205959
要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/205959
譯文內容由第三人軟體翻譯。